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Abstract 
This thesis investigates the synthesis of new fluorouracil prodrugs and new prodrug 
photosensitiser systems for medicinal applications including the design and 
preparation and attempted preparation of a novel patial cone calixarene porphyrin.  
 
The preparation of a new redox activated prodrug of fluorouracil is described. The 
biological activity of the new prodrugs was investigated against nitroreductase 
transfected cells (V79-NTR) and they were successfully activated to fluorouracil as 
determined by LC-MS. Two non-redox activated prodrugs of fluorouracil were also 
prepared and these gave activities of 15 and 20 µM against colon cancer cell lines 
.  
An attempt was made to prepare a series of porphyrazines that could be used as both 
PDT agents and carriers for the ‘dark’ therapeutic nitrous oxide. Unfortunately, 
purification of these new compounds proved unsuccessful and they were not further 
developed.  
 
Chapter three outlines the proposed design and synthesis of a new and novel 
thermally stable partial-cone calix[4]arene porphyrin. The strategy required the 
selective synthesis of a partial cone O-arylcalixarene nitrile, which was then to be 
converted to the aldehyde by reduction. The nitrile derivative was successfully 
prepared by both thermal and microwave conditions, however, the reduction of the 
nitrile to the aldehyde proved to be problematic. However, it was discovered that 
only lithium based reducing agents could reduce the nitrile, albeit in low yields. It 
was discovered that the reduction of the nitrile was steriacally hindered due to the 
presence of calyx[4]arene t-butyl groups in the upper rim. As a consequence of the 
low yields of the reduction reaction, the condensation of the aldehyde to the target 
porphyrin could not be achieved. 
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Chapter 1   Literature Review 
  2 
1.1 Introduction to Phthalocyanines 
Phthalocyanines (Pcs) are the most utilised blue and green pigments in industry as they 
are inexpensive, durable and have an intense absorption at long wavelengths of the 
visible spectrum.
1
 Phthalocyanines have found applications as; dyes, deodorants, as 
charge generation materials in photocopiers, for removal of sulphur from oil, in 
photodynamic therapy (PDT) and in data storage for optical disks.
2
 Phthalocyanine was 
first discovered in 1907 but it wasn’t until the 1930’s that the structure was elucidated by 
Sir Reginald Linstead. 
 
Scheme 1. Relationship between porphyrin and phthalocyanine, a)  basic porphyrin, b)  
a tetrabenzoporphyrin, c)  a tetraazaporphytin or porphyrazine and d)  a 
phthalocyanine.
1 
 
The most prominent methods of preparing phthalocyanines involves the cyclisation of 
phthalic acid derivatives, e.g. phthalonitrile, o-cyanobenzamide or phthalic anhydride, 
some of which are shown in scheme 2 .
2
 
Phthalonitrile, scheme 2, is by and large the most commonly used precursor for the 
preparation of phthalocyanines. The synthesis involves heating phthalonitrile in a lithium 
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alkoxide solution to produce the lithiated phthalocyanine. This PcLi2 can be de-
metallated with acid to give the metal-free PcH2 or treated with a M
+2
 salt to yield the 
metallated derivative .
3
  
 
 
 
Scheme 2. Phthalocyanine precursor compounds, where the compound in red is 
phthalonitrile.
4
 
 
A proposed mechanism for the, “Linstead method of phthalocyanine formation” is 
illustrated in scheme 3. 
5
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Scheme 3. Linstead’s proposed mechanism for phthalocyanine formation.5 
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1.1.2 Solubility of Phthalocyanines 
Phthalocyanine is notorious for its insolubility in water and most organic solvents.  This 
high insolubility is a result of strong intermolecular π-π interactions between the 
phthalocyanine rings which results in the formation of stable aggregates preventing 
solubilisation. 
1-5
 
 
Pc solubility in organic solvents can be achieved by incorporating bulky substituents such 
as neopentoxy, t-butyl or long alkyl chains into the periphery benzo groups of the 
phthalocyanine. This peripheral substitution of phthalocyanines increases solubility by 
sterically blocking the π-π stacking between phthalocyanine rings. However, even in the 
presence of these bulky groups aggregation is observed at concentrations above 10
-5
 M.   
Phthalocyanine solubility in water can be achieved by incorporating sulphonate or 
carboxylate groups into the peripheral benzo groups of the phthalocyanine. Charge 
repulsion between these groups prevents aggregation of the phthalocyanine rings.
4
 
 
Unfortunately, the aggregation of phthalocyanines at high concentrations and in the solid 
state can have a significant detrimental effect for applications that are dependent on the 
spectral properties of the Pc. Aggregation results in the loss of fluorescence and a 
broadening of the Pc Q-band (see below).  
N
NH N
HN
High aggregation - poor solubility 
in water and organic solvents
N
N N
N
M
Ligand
Ligand
Aggregation inhibited by axial
ligands resulting in better solubility
 
Figure 1. (a) Metal-free phthalocyanine, (b) Axial substituted phthalocyanine. 
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One approach used to eliminate aggregation is the incorporation of axial ligands that can 
coordinate with specific metals such as silicon and germanium (figure 1).  However, this 
approach is obviously limited and cannot be applied to other metalated phthalocyanines.
4
  
 
1.1.3 Preparation of substituted phthalocyanines 
Perhaps the most direct way of introducing substituents into the periphery benzo groups 
of a Pc is by direct electrophilic substitution (scheme 4). Substituents such as halogens 
and sulphonate groups have been introduced in this fashion to yield both phthalocyanine 
green dye (chlorinated copper Pc) and water soluble phthalocyanines (sulphonated Pc) 
that are commonly used in inks. However, controlling both the number and positional 
location of these substituents in the phthalocyanine ring is not possible, and as a result 
mixtures of products containing 4-16 subtituents are typically made. For dye applications 
this is not a problem since these mixtures give a reproducible colour, however, for more 
advanced applications, high purity is required, thus controlling both the number and 
location of substituents within the Pc ring is essential.
4
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Scheme 4. Electrophillic substitution of PcM. 
To achieve this end it is necessary to prepare the target Pcs from the appropriate 
substituted phthalonitriles. By using this approach one can control the number and, in 
some cases, the position of the substituents. 
Shown in figure 2 are some commercially available phthalonitriles.  
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Figure 2. Commercially available phthalonitriles. 
 
One key requirement for the substitutents introduced into phthalonitrile is that they must 
be stable to the harsh condensation conditions used to prepare the Pc. This does put a 
limitation as to the types of functional groups that can be used. However, substituents 
such as alkoxy, alkyl, alkynyl, alkenyl, and halogen are stable under these conditions and 
they are the most typically used substituents. Shown in scheme 5 is a typical self-
condensation of a substituted phthalonitrile to a tetra substituted Pc. It should be noted 
that unsymmetrical substituted phthalonitriles (such as 4 or 3-substituted phthalonitrile) 
will yield mixtures of positional isomers with D2h; D4h; C2v and Cs symmetries; this does 
give rise to a purity problem. Separation of these isomers has only ever been achieved in 
a few instances using HPLC. One way of overcoming the positional isomer problem is to 
cyclise phthalonitriles possessing large substituents (benzyloxy groups) in the 3 position 
of the phthalonitrile. As a result of steric hindrance only one isomer, the Cs, is made. 
Unfortunately, this approach is only useful in a limited number of situations.
6
 
The most efficient way of overcoming the positional isomer problem is to condense 
symmetrical phthalonitriles, such as 4,5 or 3,6-substituted phthalonitriles, the resulting 
Pcs are octasubstitued single isomers. 
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Scheme 5. Self- condensation of a 4-substituted phthalonitrile. 
1.1.4 Unsymmetrical substituted phthalocyanines. 
Unsymmetrical substituted phthalocyanines have gained much interest over the past three 
decades, starting with the development of binuclear Pcs for application as solar catalysts 
for hydrogen generation to the more modern areas of non-linear optics and photodynamic 
therapy of cancer. Outlined in scheme 6 is a typical methodology for preparing an 
unsymmetrical Pc, it involves the mixed condensation of two different phthalonitriles (in 
the example shown the stiochiometry is 1:1). The product obtained is a mixture of six 
different Pcs (not including positional isomers) however, efficient separation of this 
mixture is extremely difficult since the Pcs associate very strongly with each other via 
aggregation.  
To enrich one of the Pcs over the rest, specifically PcR3X1, stoichiometric control can be 
used. Typically a stoichiometry of 4:1 of the R substituted phthalonitrile to the X-
substituted phthalonitrile will give an enriched mixture of the target Pc. Unfortunately, 
purification of this mixture by silica gel chromatography cannot be achieved, there is 
always trace contamination with by-product Pcs found.
7
 However, it is possible to purify 
these mixtures using size exclusion chromatography with Biobeads SX-3 (3% crosslinked 
polystyrene), amounts of up to 50 mg can be purified per run through the column, 
yielding pure phthalocyanine product.
8
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Scheme 6. Mixed condensation of two different phthalonitriles (stoichiometry of 1:1) and 
the resultant mixture of phthalocyanines made. 
 
 
1.1.5  Characterisation – UV-Visible Spectra of phthalocyanines 
The intrinsic π-electron conjugated system of phthalocyanines leads to rich and highly 
informative electronic spectra.
9
 The Q-band arises due to a1u → eg, π → π* transition 
which gives rise to an orbitally doubly degenerate state 
1
Eu, in metallated phthalocyanines 
that have planar symmetry, thus we see one peak for the Q-band between 650 – 750nm 
(figure 3). In a metal-free phthalocyanine the symmetry is lower (D2h), thus the excited 
state has two absorptions Qy and Qx, and hence two peaks are observed in the absorption 
spectra. The weaker peaks of the B-band region are vibrational overtones of these and are 
typically found between 300 – 450nm.4,10 
  10 
 
Figure 3. The visible absorption spectra of solutions of (A) metal-free phthalocyanine 
and (B) a zinc metallated phthalocyanine.
1
 
 
The presence and nature of a central metal atom, axial ligation, peripheral substitution, 
size and symmetry of a phthalocyanine are elements that influence both the absorption 
maximum and the structure of the Q-band.
4
  
The incorporation of electron donating substituents into the 1, 4, 8, 11, 15, 18, 22, 25, 
positions of the Pc ring, figure 4, increase the energy of the Pc HOMO resulting in a 
marked red-shift (bathochromic) of the Q-band. Other substituents such as alkynes and 
benzoannulation will also red-shift the Q-band as a result of extended conjugation.
11
 
 
 
 
 
 
 
 
 
Figure 4. Phthalocyanine showing the peripheral substitution sites in blue and the non-
peripheral substation sites in pink. 
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When Pc rings aggregate (cofacial or tail-to-tail arrangement) the Q-band becomes 
broadened and blue shifted to ~ 630 nm, which results from intermolecular exciton 
coupling thereby raising the energy level of the excited state coupling.   
Unsymmetrical substituted metalated Pcs containing substituents, which can perturb the 
molecular orbital (MO) of the Pc, show uniquely split Q-band absorptions. This effect is 
demonstrated in figure 5 with a series of unsymmetrical substituted Pcs. Each of these 
Pcs possess conjugating substituents in different symmetrical substitution patterns. Since 
these substituents conjugate with the Pc macrocycle they cause a perturbation of the Pc 
molecular orbital resulting in a change in Q-band structure. This change depends on the 
symmetry of the substitution pattern. To predict the structure of the Q-Band (ie. Single 
peak, split peak) one must apply ‘Symmetry-adapted perturbation theory’ (SAPT).12 
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Figure 5. Unsymmetrical substituted Pc’s I and II, the UV/Vis spectra of Pc I (thin line), 
Pc II (solid thick line). 
  12 
The Hamiltonian of a Pc can be described by a simple equation 1.1. 
12 
H = H 
(0)
 + V                                         (equ 1.1) 
H 
(0)
 is the unperturbed Pc core Hamiltonian, unsubstitued Pc core of D4h symmetry. V is 
the perturbation caused by the substituents. The V term is a sum of perturbations which 
span an irreducible representation for D4h symmetry.(Equation 1.2)   
V= V1 + V2  + ······                             (equ 1.2) 
V1, V2,…are the corresponding symmetry-adapted perturbations. 
The V term can be described by symmetry elements: A1g; B1g; Eu,y and B2g symmetry 
elements. If the symmetry elements B1g and B2g are present then a perturbation of the Pc 
molecular orbital will occur resulting in a splitting of the Q-band. All of this can 
simplified into a straight forward graphic shown in figure 6.  Based on the graphical 
analysis for Pc II the symmetry elements B2g and B1g are present (their contribution does 
not equal zero) and as a result a splitting of the Q-band is observed. 
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The IR spectral characteristics of metal-free phthalocyanines show N-H stretching from 
3090 – 3290 cm-1, N-H deformations between 1005 – 1025 cm-1 and 720 – 750 cm-1, and 
C-H stretches appear c. 3000 cm
-1
.
Error! Bookmark not defined.
 
The extinction coefficient of an intense Q-band would generally be 2 x 10
5
 cm
2 
mol
-1
 for 
a phthalocyanine.
1-5
 
 
1.2 Calixarenes.  
Calixarenes are basket shaped compounds, composed of repeating phenyl rings with 
methylene spacers between each ring. They are typically prepared by the condensation of 
para-substituted phenol with formaldehyde 
13
. Calixarenes most commonly reported in 
the literature are tetramers (composed of four repeating phenolic units and referred to as 
calix[4]arenes). These calix[4]arenes can assume four different conformations 
14
: cone, 
where the four hydroxy groups are positioned on the lower rim of the molecule; partial 
cone, where one of the phenolic units flips 180° so that its hydroxy  groups is positioned 
on the upper rim; 1,2-alternate, where two adjacent phenolic units flip 180º or 1,3-
alternate where two opposite phenolic units flip 180º (see figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  15 
 
 
 
 
Figure 7. The four conformations of calix[4]arenes, (a) cone, (b) partial cone, (c) 1,2 
alternate, (d) 1,3 alternate. 
 
To lock the calixarene into the cone conformation bulky tert-butyl groups are introduced 
into each of the phenol units at the upper rim, effectively maintaining the basket shape of 
the tetramer.
15
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PPM 
Figure 8.
 1
HNMR of p-tert-butyl-calix[4]arene.
16
 
 
Each conformation of the calix[4]arene has its own unique 
1
H NMR spectrum. In the 
spectrum of the cone conformation of p-tert-butylcalix[4]arene the hydroxy protons are 
found at approximately 10.3 ppm, the aromatic protons appear just above 7 ppm, the 
methylene bridge protons, are present as doublets at 3.48 ppm and 4.24 ppm (J
2
 coupling) 
and the tert-butyl protons are at 1.2 ppm, as illustrated in figure 8 above.  The spectrum 
of each of the other conformations differ from that of the cone and are most easily 
elucidated by their methylene bridge features as outlined in table 1. 
 
  17 
 
Conformation Variation in 
1
HNMR Peaks 
Cone One pair of doublets 
Partial Cone 
Two pairs of doublets of equal intensity and the 
possibility of a singlet of the same intensity. 
1,3-Alternate One singlet 
1,2-Alternate One singlet and two doublets of equal intensity 
 
Table 1. 
1
HNMR patterns for the CH2 bridging protons in the various conformations of 
calix[4]arene 
16
. 
 
Calixarenes and their analogues have been exploited in many areas including, host-guest 
chemistry, enzyme mimics
17
, chiral recognition and optical sensors.
18
 
 
1.2.1 Substitution Reactions of Calixarenes.  
The selective chemical modification of calixarenes can be achieved making them 
excellent precursor compounds for more complex molecular assemblies.
19
  
 
 
 
Figure 9. Calixarene segments . 
 
Calixarenes can be readily functionalised via substitution at either the upper rim or lower 
rim.  Substitution at the upper rim, as shown in figure 10, can be used to introduce water 
solubility if desired.  
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Figure 10. Upper rim functionalised calixarenes. 
 
 
Figure 11. Example of upper rim substitution of a calixarene and the complex structures 
that can be formed. This is an example of a cofacial bis-porphyrin calixarene.
19
 
 
Upper rim substituents that have been employed in the past include acids, tert-butyl 
groups, amines and porphyrins and have in some cases led to complex and interesting 
molecular assemblies, figure 11.   
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Scheme 7. Some examples of lower rim substituted calix[n]arenes.
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Lower rim functionalisation has been carried out most commonly with acetates, amides, 
polyethylene glycol, alkyl groups and benzyl groups (scheme 7). Methods of lower rim 
modification are most frequently achieved by refluxing calix[4]arene, an appropriate 
alkylating agent and a base in DMF or acetone. The choice of base (potassium carbonate, 
sodium carbonate, sodium hydride) will affect both the degree and pattern of substitution. 
Interestingly, weaker bases with small counter cations give partial substitution of a 1,3-
distal pattern (K2CO3, Na2CO3) and stronger bases such as NaH ( in the presence of an 
excess of alkylating agent) results in  full substitution on the lower rim of the calixarene. 
Shown in Scheme 7 are selected examples of lower rim functionalised derivatives. The 
ester derivatives have found application in sodium selective sensors, the phosphine oxide 
derivatives have excellent potential as nuclear waste extractants. 
  20 
 
 
Scheme 8.  The preparation of a distal 1,3- dimethoxycalix[4]arene. 
The ability to be able to prepare partial-lower-rim substituted calixarenes such as the 
distal-1,3-dimethoxycalix[4]arene, scheme 8, give rise to the possibility of creating 
compounds that are more functionally diverse some recent examples of which are shown 
in scheme 9.
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Scheme 9. Examples of novel derivatives that can be prepared from distal-1,-
dimethoxycalix[4]arene.
20
 
 
Outlined in Scheme 10 is the preparation of a novel distal substituted calix[4]arene that 
can be used in the extraction of nuclear waste. The preparation of this novel compound 
  21 
involves the use of a weak base to achieve partial alkylation of p-tert-
butylphenolcalix[4]arene,  scheme 10, thus avoiding substitution at all four hydroxy 
positions. To fully substitute the calix[4]arene a strong base such as NaH in an aprotic 
solvent with a large excess of alkyl halide would be required.
21
 The distal-1,3-
dimethoxycalix[4]arene is of interest in this project as it is a required precursor in the 
synthesis of our o-arylated calixarenes. 
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Scheme 10. Preparation of a novel 1,3-distal calixarene used in nuclear waste 
extraction. 
 
The reason the distal di-substituted calix[4]arene is obtained when using a weak base 
instead of the completely alkylated calix[4]arene is because the two remaining 2,4-OH 
groups are stabilised by H-bonding making them less acidic. It is broadly acknowledged 
that in lower rim oppositely substituted calixarenes in the cone conformation, the hydroxy 
groups are involved in H-bonding (figure 12).
22
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Figure 12. Hydrogen bond stabilisation of 1,3-disral charged calix[4]arene intermediate 
vs the 1,2-charged intermediate.
 
 
  
The use of different alkylating agents to prepare lower rim modifications to the 
calixarenes can give rise to conformationally different products. Thus, there not only 
exists the possibility of controlling the substitution pattern on the lower rim of 
calix[4]arene, but in some cases one can also control the resulting conformation of the 
calixarene. It should be noted that the resulting conformations shown in scheme 10 can be 
locked if the substituents on both the upper and lower rim are large enough to prevent 
rotation of the calixarene phenolic units through the annulus of the calixarene. It has been 
found that the introduction of alkyl groups, longer than propyl, immobilises the 
calixarene conformations. 
 
1.2.2 O-arylation of calix[4]arenes 
The archives of o-aryl ether calixarenes to date have been sparse, with only one 
publication prior to 2001 by C David Gutsche in 1979. Gutsche prepared mono-, di- and 
hexa-2,4-dinitrophenyl ether derivatives of tert-butyl calix[8]arene. These were prepared 
from p-tert-butylphenol and formaldehyde in the presence of a base to procure 
calix[8]arene which was then treated with 2,4-dinitrochlorobenzene to obtain the ether 
derivative, (scheme 11).
22
 
   23 
 
Scheme 11. Preparation of the first partial substituted o-arylated calixarenes.
23
  
 
Following on from Gutsche, Paris E. Georghiou prepared the first lower rim substituted 
aryl ethers of p-tert-butylcalix[4]arene. Georghiou achieved this through a nucloephilic 
aromatic substitution reaction of 4-fluoro-3-nitrobenzaldehyde with K2CO3 in DMF. 
Varying the concentration of 4-fluoro-3-nitrobenzaldehyde from two equivalents to an 
excess, produced mono-, di- and tri-aryl ether products respectively (scheme 12).
23
   
 
OHOH HOO
K2CO3
DMF
X
NO2
F
X = CHO, CH2OH, CO2C2H5
OROR ROO
 
Scheme 12. Synthesisof o-aryl ether calix[4]arene.
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Finally in 2007 the Nolan group prepared both the di-methoxy and tri-methoxy analogues 
of p-tert-butyl-(dicyanobenzene)calix[4]arene.
20
 This was accomplished using methyl 
iodide and K2CO3 in DMF to prepare the distal-1,3-di-methoxycalix[4]arene, which was 
further reacted with nitrodicyanobenzene in K2CO3 in DMF producing the o-aryl ether 
calixarene. Further methylation generates the trimethoxy analogue, scheme 13.  
 
*
OH O
NO2
NO2
*
OH
8
n m
Pyridine
O2N NO2
Cl
(a) = (n=6, m=2)
(b) = (n=1, m=7)
(c) = (n=2, m=6)
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Scheme 13. Preparation of self filled partial cone 5,11,17,23,-tetra-t-butyl-26,27,28-
trimethoxy-25-(-3-[1,2-dicyanobenzene])calix[4]arene. 
20
 
 
Upper rim substituted calix[4]arenes are of significance to this project, and the first ever 
example is the partial cone 5,11,17,23-tetra-tert-butyl-26,27,28-trimethoxy-25-(-3-[-1,2-
dicyanobenzene])calix[4]arene. These compounds contain an aromatic ring in the upper 
annulus of the calix[4]arene, they are quite inflexible to conformational change and they 
have been proven by NMR temperature studies to be conformationally stable to over 
140°C (figure 13).  
The 
1
H NMR spectrum of the partial cone calix[4]arene, (figure 13), reveals the 
methylene bridge protons are relatively unchanged  when compared with the signals of p-
tert-butyl calix[4]arene in figure 8. The additional peaks of the phthalonitrile susbtituent 
are found upfield at 3.5 ppm (triplet), 4.5 ppm (doublet) and 6.4 ppm (doublet). The 
protons of the phthalonitrile group are shifted up-field from their typical values of 7-8 
ppm as a result of anisotropic shielding caused by the aromatic annulus of the 
calix[4]arene (see table 2).
20
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PPM 
Figure 13. 
1
H NMR of the partial cone 5,11,17,23-tetra-tert-butyl-26,27,28-trimethoxy-
25-(-3-[-1,2-dicyanobenzene])calix[4]arene. 
 
 
 
Distal Di-methoxy 
Calixa[4]rene  
Partial Cone Calix[4]arene 
Inclusionary Complex  
t-butyl 2 singlets (ratio 1:1) 3 singlets (ratio 1:1:2) 
Methylene bridge Pair of doublets (ratio 1:1) 2 pairs of doublets (ratio 1:1) 
Aromatic 2 signals 4 signals 
 
Table 2. Comparison of the 
1
H NMR spectra of distal-di-methoxy calixa[4]rene  and the 
partial cone calix[4]arene. 
As mentioned earlier, the partial cone conformation is temperature stable to at least 
140°C as determined by temperature 
1
H NMR, figure 14. One point of note in the 
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temperature study is that the triplet representing the aromatic phthalonitrile H5 proton is 
shifted slightly downfield with an increase in temperature, this is thought to be due to the 
slight movement of the aryl substituent within the calixarene upper rim. 
 
 
 
Figure 14. 
1
HNMR temperature study of the self filled partial cone 5,11,17,23-tetra-tert-
butyl-27-hydroxy-26,28-dimethoxy-25-(-3-[-1,2-dicyanobenzene])calix[4]arene. 
20
 
 
1.3 Brief history of Photodynamic Therapy (PDT). 
At the beginning of the last century the concept of cell death by an interaction between 
light and chemicals was discovered by Oscar Rabb, a medical student of von Tappeiner. 
He serendipitously observed the toxic and deadly outcome of administering acridine red 
while light was being directed at paramecium Infusora during a thunderstorm. 
Concurrently J. Prime described photosensitivity in an epileptic patient who displayed a 
reaction to eosin when exposed to the sun and consequently Tappeiner and Jesionek 
carried out one of the first treatments of skin tumours with white light and eosin, reported 
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in 1903. Following on from Rabb’s innovative breakthrough, in 1907 von Tappeiner and 
Jodlbauer established that oxygen was fundamental in the cell death process.
24
 
 
There are two phototherapeutic approaches established for cancer treatment, 
phototherapy and photochemotherapy. Phototherapy occurs when the application of light 
to cancerous tissue causes cell death via molecules already present in the cancerous 
tissue. Photochemotherapy involves the administration of a photosensitizing agent that 
selectively accumulates in cancerous tissue and becomes activated upon irradiation with 
light of an appropriate wavelength to cause cell death. 
24,25
 
 
Photodynamic therapy (PDT) requires a photosensitizer, light and oxygen. The 
photosensitizer is administered and preferentially builds up in cancerous tissue; this is 
followed with the application of light of the appropriate wavelength (620 nm – 750 nm) 
thus initiating the photodynamic process. Following light absorption, energy is 
transferred to molecular oxygen, which yields reactive singlet oxygen as outlined in 
figure 15 that is capable of causing direct cell death, vascular shutdown and local damage 
via inflammatory and immune mediators. Two well known PDT photosensitizers in use 
are the first generation drug Photofrin® and the second generation drug Verteporfin. 
26
,
27
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Figure 15. Mechanism of photosensitized singlet oxygen production.
24,25
 
 
In figure 15, light is applied to the photosensitizer, causing it to become excited from its 
ground state to its singlet excited state (S0 → S1). The excited photosensitizer can then 
decay via fluorescence or internal conversion, or it can undergo intersystem crossing 
(electron spin conversion) to the long lived reactive triplet state (S1 → T3). At this point 
the triplet state photosensitizer can be quenched via oxygen or substrate to yield the 
oxygenated products. The generation of singlet oxygen and super oxide anions are the 
predominant mechanism of cell death and are known as type II reactions. Type I occurs 
via quenching by solvent or substrate molecules, which yield the corresponding radicals. 
The cellular targets for PDT are the mitochondria, lysosomes, cell nucleus and cellular 
membrane. 
27,28,29
 
 
Note: High energy 
light (<750nm) is 
required as much 
energy is lost by 
molecular oxygen 
through vibrations 
in it’s conversion 
to singlet oxygen. 
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However there are many problems with the current PDT medications on the market. 
There are many factors to consider in the development of an effective photosensitizer 
which are listed below: 
1) The photosensitizer must absorb light in the region 600-750nm with extinction 
coefficients greater than 100,000 and  it should have high quantum yields for the 
generation of  
1
O2,  
2) The photosensitiser  needs to be photostable (i.e not break down or degrade in any 
way under the application of light) and stable to 
1
O2, O2
-
 and the radicals or 
oxygenated species produced in situ,  
3) The photosensitiser must show no “dark toxicity” prior to application of light and 
before the drug has reached its target, it should be site specific (selectively target 
cancer tissue),  
4) The photosensitizer should be a single pure compound (i.e. not a mixture of 
photosensitizer compounds as is the case with photofrin that is presently used 
clinically),   
5) The photosentiser should be easily and quickly expelled from the body after the 
treatment is finished. 
 
The original PDT sensitizer that came to market in the 1990’s, Photofrin®, had many 
problems, from impurity and inappropriate absorption wavelength to low extinction 
coefficient and prolonged lingering of the drug in the body.
30
 Verteporfin, a second 
generation photosensitiser, has significantly improved properties with respect to 
improved extinction coefficieint, absorption outside of the biological window and an 
efficient clearance from the body. However, there are other ways in which PDT 
photosensitizers can be advanced and progressed. For example, an increase in the 
potency of the photosensitizer can be achieved through by combining the 
photosensitiser with other known cancer killers such as NO and 5-fluorouracil. 
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1.4 Nitric Oxide 
Nitric oxide (NO) plays an important role as a cell-signalling molecule, anti-infective 
agent and as an antioxidant. Also it is well established that nitric oxide is formed as an 
immune response to pathogen invasion in mammalian biology. 
31
 Thus, it is no surprise 
that NO donating complexes are being investigated for medicinal  purposes, with specific 
applications for the treatment of vascular disorders, cancer  and Alzheimer’s disease. 32 In 
addition to this, NO has displayed an ability for sensitisation of hypoxic cells to ionizing 
radiation 
33
 which has the potential to augment cell death in PDT. Therefore it follows 
that the development of a PDT sensitizer that can release nitric oxide in cancerous tissue 
would create a more potent anti-cancer drug. A porphyrin complex that generates nitric 
oxide upon irradiation has been synthesised and investigated.
34
 
 
 
 
Figure 16. Roussin’s Red Salt ester (RSE) and Protoporphyrin IX RSE (PPRIX-RSE), 
which have shown promise as photochemical NO precursors. 
34
 
 
Roussin’s red salt (RSE) releases NO upon radiation at 365 mn, however since this 
wavelength is not suitable for use in PDT of mammalian cells, the protoporphyrin IX 
chromophore which has higher absorbance at longer wavelenghts was investigated 
(figure 16). It was found that PPIX-RSE is efficient at absorbing light and transferring 
energy from the porphyrin to the RSE cluster, and thus ultimately leads to the NO 
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release.
34
 This example of an NO releasing PDT agent illustrates that such systems are 
viable prodrug targets. 
 
1.4.2  5-Fluorouracil 
5-fluorouracil (5-FU) (figure 17), a fluorinated pyrimidine, has been broadly used in the 
treatment of cancerous tumours including but not limited to pancreatic, lung, esophegal 
and gastric cancer.
35,36,37,38,39
 5-FU kills cancer through the following three actions:  
1. DNA synthesis inhibition via thymidylate synthase, which yields 5-
fluorodeoxyuracil monophosphate. 
2. Integration into DNA as 5-fluorodeoxyuracil triphosphate. 
3. Integration into RNA as 5-fluorodeoxyuracil triphosphate. 
 
However, 5-FU brings with it undesirable and non-discriminate toxicity to healthy cells. 
Therefore many studies and much research have been carried out to develop more site 
specific methods of delivering this drug to its specific site of action including prodrug 
development, thus avoiding the healthy cells on its path. In addition work has been done 
to improve its cytotoxicity to cancerous cells through investigation of more efficient and 
effective derivatives. 
 
 
 
Figure 17. 5-Fluorouracil. 
 
5-FU prodrugs can be divided into two categories, nucleoside prodrug derivatives and 
base prodrug derivatives. As base derivative prodrugs are of most relevancy to this 
project, I will not be discussing the nucleotide class. The base derivatives are most 
commonly formed through modification at the 
1
N position
40
, as this is the more reactive 
nitrogen synthetically, however alterations at the 
3
N position have also been reported.
28
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Improvements in cytotoxicity to cancerous cells and/or reduction in toxicity to healthy 
cells have been achieved for derivatives with some of the following alterations: 
 
1. Incorporation of a carbonyl group at the 1N position, as illustrated in figure 18.41 
N
NH
O
O
F
O R
R = Alkyl or phenyl  
Figure 18. Base Derivatives of 5-FU. 
2. Introduction of alkoxybenzyl or alkoxyphenylsulfate substituents, again at the 1N 
shown in figure 19.
42
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Figure 19. 5-FU derivatives. 
3. Various other derivatives with both open and closed chains added with a 2-
oxogroup, shown below in figure 20, have been explored, and as reported by Mori 
et al, the presence of an oxygen in this arrangement aids the release of 5-FU from 
the prodrug structure through easier dissociation of the C-
1
N bond, thus yielding 
high anti-tumour activity (47-96%).
43
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Figure 20.  5-FU-2-coy open chain derivative open chain and 5-Fluorouracil -1-(2’-
oxycyclalkyl)uracil derivative. 
 
4. Nitrobenzyl compounds have shown toxicity to hypoxic cells. Hypoxic cells are 
often found in cancerous tissue, they occur as a result of a) cells being adequately 
distant from the nearest blood capillary for long periods of time, b) temporary 
shutdown of blood vessels causing temporary hypoxia in cells. Essentially 
hypoxic cells lack oxygen. Thus the inclusion of nitrobenzyl groups into 5-FU 
(figure 21) creates a bioprecursor prodrug that is activated in hypoxic tissue by 
reductases to yield two cytotoxic moieties; qiononemine methides and 5-FU a 
very potent mixture.
44,45
 
 
 
 
 
 
Figure 21. Prodrug – 3-(p-nitrobenzyloxycarbonyl)-5-fluorouracil. 
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1.5 Project Proposal 
The principal aim of this work is to design a new anticancer prodrug system that is 
selective for tumor tissue and which gives reduced cytotoxicity to normal cells. The 
proposed design involves a novel modification of the established anticancer drug 5-
flourouracil, to create a new prodrug. Outlined in Scheme 14 is the proposed strategy. 
This strategy involves the conjugation of 5-flourouracil to both a bioprecursor and to a 
carrier linker.  The bioprecursor is a nitro aromatic compound that on enzymatic 
reduction is converted to the cytotoxic quinomethane and releases the fluorouracil (see 
scheme 15).
44
 The carrier linker is a photosensitizer such as a phthalocyanine or 
porphyrin, which will selectively localize the entire prodrug system toward cancerous 
tissue and can also be used as a light therapeutic agent if desired.  
 
The nitroaromatic system was chosen as the bioprecursor since nitro-aromatic 
compounds have shown toxicity to hypoxic cells. The toxic                                                                                                                                              
compounds, qiononemine methides, are formed when the nitro-aromatic compound is 
enzymatically reduced (scheme 15). Upon this reduction the 5-flourouracil drug is 
released and therefore there are two cytotoxic moieties available, thus increasing the 
potency of the prodrug. It is hypothesised that this reduction will be activated by the 
reductase produced by a tumour to combat the oxidative stress of Photo Dynamic 
Therapy.
44
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Scheme 14. Proposed scheme for the incorporation of the bioprecursor protected 5-
flourouracil into the phthalocyanine photosensitizer carrier linker. 
  
The carrier linker used will also have photocytotoxic effects in cancerous cells, as it is a 
phthalocyanine photosensitiser. The phthalocyanines have been applied in the PDT of 
tumours, as outlined in section 1.4. They selectively accumulate in cancerous tissue and 
are activated by the application of light of a specific wavelength (< 800 nm).  
We are also interested in developing a new prodrug that can incorporate nitrous oxide. 
Nitrous oxide is a very effective anticancer agent and we believe it is possible to 
incorporate nitrous oxide organometallic groups into a phthalocyanine via carbene co-
ordination.  Outlined in Scheme 16 are the proposed final structures for both prodrug 
systems.  
   36 
 
Scheme 15. Reduction of bioprecursor prodrug to drug plus cytotoxic quinonemine 
methides. 
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Scheme 16. The proposed nitrous oxide phthalocyanine prodrug. 
 
 
Previous work carried out in the Nolan research group involved the development of new 
5-FU prodrugs. Shown in figure 22 is the structure of a new lead hit, this compound 
possesses a higher bioactivity than 5-FU and was also found to be active against 5-U 
resistant cell lines  
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Comp IC50 Values 4T1 cell 
Line 
IC50 Values SW480 
cell Line 
 3 Days 5 Days 3 Days 5 Days 
 g/ml g/ml g/ml g/ml 
 
5-FU 
 
0.05 
 
0.02 
 
0.80 
 
0.40 
 
1 
 
0.009 
 
0.005 
 
0.40 
 
0.06 
 
 
Figure 22. Biodata for new 5-FU derivative.
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It was initially thought that 1 acts simply as a prodrug of 5-FU, that is 1 is converted to 5-
FU through hydrolysis of the carbonate substituents. However, cell cycle studies have 
revealed that the activity of 1 is different from 5-FU, thus 1 does not behave as a prodrug 
but as a unique new lead. 
It is one of the goals of this research to carry out a structure activity relationship (SAR) 
study on 1 to: 
Control 5-FU 
Cmpd 7 
Cell cycle analyses of 4T1 cells following 3 days treatment with 0.1mM 5-
FU and 5-FU derivatives.  X-axis shows DNA content, y-axis represents 
counts of cell.  G1 phase is in light blue, S phase in pink and G2 phase in 
dark blue.  
Cell cycle analyses of 4T1 cells 
NH
N
O
O
F
O
OO
NH
N
H
O
O
F
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1) determine what structural aspects of the carbonate handle are required for this 
unique activity , 
2) use the information from this SAR study to develop a potentially better lead. 
In tandem with this work it is envisaged to develop an interesting novel calixarene 
porphyrin. These compounds are to possess a partial cone calix[4]arene platform with a 
porphyrin (figure 23). The resulting porphyrin should be partially picket fenced, that is 
the metal centre of the porphyrin will be isolated, as a result such a compounds should act 
as potential oxidation catalysts and biomimitec sensors (Haemoglobin) with respect to 
reversible oxygen binding.  
 
 
Figure 23. Proposed calixarene porphyrin. 
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Chapter 2    Synthesis and Characterisation of Novel Third Generation 
PDT Produrgs 
   41 
Introduction 
 
2.1 Synthesis of 5-Fluorouracil Derivatives 
5-fluroruracil (5-FU), as delineated in the literature survey, is a well established and 
reviewed anti-cancer drug, and as such was considered ideal for study, modification and 
improvement. Two types of nitroaromatic derivatives and two alkyl chain derivatives 
were prepared in this work. The logic of the design, synthesis and characterisation of 
these derivatives are described below. 
 
2.1.1 Trigger-Linker-Effect 
The trigger-linker-effect concept was used in the design of the 5-FU derivatives (figure 
24).
47
 In the nitroaromatic compounds, the reduction of the nitro group by reductases 
essentially triggers the release of the active drug from the tripartite prodrug under 
hypoxic conditions
48,49
, thus these compounds are expected to have selectivity as they 
should not become reduced in healthy oxygenated cells.
50
 The choice of linker between 
5-FU and the nitro-aromatic trigger will ideally facilitate the release of the drug and 
cytotoxin from the bio-precursor complex. The formate linker shown in figure 24 below 
fits these requirements. 
 
Trigger----------------Linker----------------Effecter 
NO2 --------benzyl-chloroformate-------5-FU 
 
 
Figure 24. Trigger-linker-effect concept. 
51
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The synthesis of compound 1 and its partner, the di-substituted 5-fluorouracil 2, was 
achieved by heating 5-fluorouracil in 37% formalin at 60°C for 45 minutes. The resulting 
product, an oil, was dissolved in acetonitrile after being dried under vacuum. An 
equimolar portion of triethylamine and 4-nitrobenzyl chloroformate were reacted with the 
5-FU solution resulting in yields of 15% and 37% of 1 and 2 respectively (scheme 17). 
 
 
 
Scheme 17. Preparation of 1-nitrobenzyloxycarbonyloxymethyl-5-flourouracil 1 and 1,3-
nitrobenzyloxycarbonyloxymethyl-5-flourouracil 2. 
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Biological studies on 1 and 2 were carried out at UCD by Dr Aisling Redmond under the 
supervision of Dr Susan Mc Donnell. The biological assay used was an in vitro assay 
using cancer cell lines that were transfected with bacterial nitroreductse (V79-NTR) and a 
standard was also run on normal V79 cancer cells as a comparison. It was found that 
neither compound 1 or 2 showed biological activity with the transfected cells. For activity 
to be observed it is essential that the nitrobenzyl substituent be reduced to a quinmethide 
thereby releasing fluorouracil, but this did not occur. This lack of biological activity 
contrasts with a similar derivative prepared earlier in Dr Nolan’s group shown in figure 
25. 
N
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3  
Figure 25. Redox activated prodrug 3. 
 
It was proven by both biological assay with nitroreductase transfected cells and 
metabolite analysis using HPLC-MS (method was developed in the NICB at DCU by Dr 
Robert O’Connor and Dr Rachel Wall) that release of 5-FU occurred by reduction of the 
nitrobenzyl group (figure 26). It would appear that the introduction, of a methyl spacer 
between 5-FU and the nitrobenzyl carbonate has a significant impact on biological 
activity.  
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Figure 26. HPLC-MS metabolite results of nitroreductase transfected cells (V79-NTR) 
treated with 5-FU (left side) and the metabolites of prodrug 3 (right side). 
 
A: 5-FU/Cmp 3  alone 
B: Cmpd 3 incubated with V79-Control cells, 5 days 
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2.1.2 5-FU alkyl chain derivatives. 
It was previously found that 1-aloxycarbonyloxymethyl-5-flourouracil 4, figure 27 has 
higher bioactivity against 4T1 and SW480 tumour cells than 5-FU.  It was of interest to 
determine the important structural features of this compound that are required for 
enhanced bioactivity. To achieve this aim a series of new derivatives were prepared to 
determine the effect of chain length and type, (i.e. the effect of saturating the bond) on 
biological activity (Figure 28). 
N
NH
O
O
F
O O
O
4  
Figure 27. 1-A1loxycarbonyloxymethyl-5-flourouracil (4). 
 
A propyl chain was chosen to replace the allyl group in 4, by doing this the effect of the 
double bond on biological activity can be determined (compound 5 figure 28). A butyl 
chain was also chosen to determine the effect chain length has, if any, on bioactivity 
(compound 6).  
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Figure 28. 1 -propyloxycarbonyloxymethyl-5-flourouracil 5 and 1-
butyloxycarbonyloxymethyl-5-flourouracil 6. 
 
 
   46 
The alkyl derivatives were prepared using the same method as that used for the nitro 
derivatives, with the only exceptions being the chloroformate reagent used and a slightly 
shorter heating time for the hydroxylated 5-FU complex. Propyl chloroformate and butyl 
chloroformate were employed to produce 5 and 6 respectively, yielding 37% of 1-
propyloxycarbonyloxymethyl-5-flourouracil 5 and 40% of 1-
butyloxycarbonyloxymethyl-5-flourouracil 6 (scheme 18 and scheme 19). 
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Scheme 18. Preparation of 1-propyloxycarbonyloxymethyl-5-flourouracil (5). 
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Scheme 19. Preparation of 1-butyloxycarbonyloxymethyl-5-flourouracil( 6). 
 
Both compounds 5 and 6 have now been evaluated for activity against colon cancer cell 
lines by Dr Susan McDonnell’s group at UCD. Both compounds have shown similar 
cytotoxicity toward the colon cancer cell lines at values of 15 and 20 μM , which is 
comparable to the biological activity of 5-FU which typically ranges from 15-20 μM on 
the same cell lines. These values are an order of magnitude lower than the allyl derivative 
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4 (1-5 μM), indicating that the double bond is essential for enhanced activity. Cell cycle 
studies are not yet available to determine whether the new derivatives behave similar to 4, 
or are simply acting as a 5-FU prodrug, (that would be the case if the cell cycles are 
equivalent to 5-FU). Biological studies are still pending. 
 
2.2 Synthesis of the porphyrazine prodrug carrier. 
 
The preparation of tetra-imidazolium porphyrazine was attempted in order to generate a 
pophyrazine where four of the peripheral carbons can be converted to their carbene form 
by removal of the highly acidic proton (scheme 20). Thus, it was hoped to create a 
platform for linking the organometallic nitric oxide compound to the porphyrazine by 
carbene co-ordination. Outlined in scheme 21 is the proposed strategy and intended 
product.  
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Scheme 20. Proposed carbene porphyrazine complex via acidic proton removal. 
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Scheme 21. Preparation of a porphyrazine complex and subsequent binding of NO. 
 
However, the self-condensation of 1-phenyl-4,5-dicyanoimidazole could not be achieved 
in pentanol at high temperature. At this point it was decided to cross condense 1-phenyl-
4,5-dicyanoimidazole with 4,5-dicyanoimidazole in pentanol at high temperature. 
Various ratios of the reactants were used, from 1:15 moles to ratios of 1:6.66, table 3, 
(based on ratios taken from the literature) however no product was procured from these 
efforts.  
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Table 3. Conditions employed in initial attempted porphyrazine synthesis. 
 
One possible explanation for the failed condensation can be taken from Linstead’s 
proposed mechanism of phthalocyanine formation. In his mechanistic analysis, scheme 3 
Chapter 1, the red arrow illustrates that the alkoxy attacks the most electropositive 
carbon, that of the nitrile group, to initiate the cyclisation and condensation process.  
However, imidazole possesses an acidic proton at position 2 in the ring (pKa 14.52) 
(scheme 22). It is quite possible that the base is deprotonating imidazole preventing the 
formation of porphyrazine. 
 
 
Scheme 22.  Proposed explanation for failed porphyrazine formation, showing proton 
that is susceptible to alkoxy attack 
 
2.2.1 Synthesis of 1-benzyl-28H,30H-tribenzo[b,g,l]imidazolo[4,5-q]porphyrazine 
The preparation of 1-butyl-7,10,14,17,21,24-hexahexyl-28H,30H-
tribenzo[b,l,g]imidazole[4,5-q]porphyrazine had been previously reported in the literature 
by J. Bakboord et al (figure 29).
52
 This method involved the cross condensation of 
dicyanoimadazoles with a partner phthalonitrile to yield a tribenzoporphyrazine.  
 
29:28 mmoles Reaction Time Temp 
1 : 150 24 hrs 150°C 
1 : 9 24 hrs 110°C 
1 : 6.67 24hrs 150°C 
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Figure 29.  Porphyrazine compounds prepared by Bakboord et al. 
 
Bakboord’s method was employed using 1-phenyl-4,5-dicyanoimidazole and 
phthalonitrile in a 1:6 molar ratio respectively in Li/pentanol at 115 
o
C (Scheme 23) . The 
reaction was allowed to proceed for 24 hours and a deep green pigment product was 
isolated.
53
 The compound was first cleaned on a silica gel column and next it was purified 
on a 3% cross linked polystyrene (SX3) size exclusion column. This separated the 
porphyrazine from the phthalocyanine by-product. 
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Scheme 23.  Preparation of 1-benzyl-28H,30H-tribenzo[b,g,l]imidazolo[4,5-
q]porphyrazine 7. 
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The isolated unsymmetrical porphyrazine was characterised by UV-Vis spectroscopy, 
which displayed two principal peaks in the Q-band region of the spectrum, which is 
indicative of metal-free phthalocyanine. One of the peaks in the spectrum, at 643 nm has 
a small shoulder of which was perturbed, confirming the presence of an unsymmetrical 
phthalocyanine (3:1 macrocycle).  However, the shoulder peaks at 616 nm and 585 nm 
are very intense indicating the presence of other phthalocyanine impurities (figure 30).
54
 
Further chromatographic separation was attempted using both silica and size exclusion 
chromatography unfortunately the target phthalocyanine could not be isolated in pure 
form.  
 To solve the purification problem a new analogue, 1-butyl-28H,30H-
tribenzo[b,g,l]imidazolo[4,5-q]porphyrazine, was prepared as the zinc derivative and not 
the metal-free. There is previous evidence that metallated unsymmetrical phthalocyanines 
are easier to separate using SX-3 cross linked polystyrene than the metal-free 
counterparts. 
55
 
 
 
Figure 30. a) UV-Vis spectrum of 1-benzyl-28H,30H-tribenzo[b,g,l]imidazolo[4,5-
q]porphyrazine 7 and metal free phthalocyanine. b) An example of a pure metal free 
phthalocyanine 
 
 
Perturbation 
a) b) 
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The preparation of 1-butyl-28H,30H-tribenzo[b,g,l]imidazolo[4,5-q]porphyrazine is 
outlined in scheme 24. The required starting material, 1-butyl-4,5-dicyanoimidazole, was 
prepared using triethylamine, tetrabutylammonium iodide, 4,5-dicyanoimidazole, methyl 
ethyl ketone and butyl bromide; the reaction was refluxed for four days. Purification was 
achieved on a silica gel column, with ethyl acetate as eluent. 1-Butyl-4,5-
dicyanoimidazole was then employed in the synthesis of the porphyrazine, which was 
achieved using the same condensation method previously described giving crude Pc 
product in 74% yield. The crude Pc product was then metallated using zinc acetate. 
Purification was carried out by initially cleaning the product mixture on a silica gel 
column, followed by size exclusion chromatography with SX-3 biobeads.  
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Scheme 24. Preparation of 1-butyl-28H,30H-tribenzo[b,g,l]imidazolo[4,5-
q]porphyrazine 8. 
 
   53 
The UV-Vis spectrum of the isolated porphyrazine, figure 31, displayed two intense 
peaks at 649 nm and 670 nm, with a small perturbed shoulder peak at 621 nm. Based on 
SAPT theory (Chapter 1) we would expect there to be two peaks observed for this 
porphyrazine, since both B1g and B2g symmetry elements are present. The observed UV-
Vis spectrum which possesses two peaks at 649 and 670 nm supports this conclusion. 
Furthermore, the two peaks are separated by 21 nm, this magnitude of separation is 
typical for this class of phthalocyanine based on previous examples prepared in the past. 
 
Figure 31. UV-Vis spectrum of 1-butyl-28H,30H-tribenzo[b,g,l]imidazolo[4,5-q-zinc-
]porphyrazine 8. 
 
To determine if the full 24 hour reaction period was required for formation of the 
unsymmetrical porphyrazine a time versus reaction progression study was carried out. 
The reaction was initiated according to the procedure outlined in the experimental 
section; a green dye formed almost instantaneously after the addition of lithium. An 
aliquot was taken each hour thereafter to monitor progress in the first six hours of the 
reaction and then the final aliquot was procured the following morning (figure 32). The 
results are described in table 4. 
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Time TLC Spots UV-Vis peaks (nm) 
1hr Brown + Green 660 - highly perturbed, 631, 598 
2hrs Brown + Green 655 - highly perturbed, 630, 596 
3hrs Brown + Green 662 - perturbed, 631, 597 
4hrs Brown + Green 660, 631, 597 
5hrs Brown + Pink + Green + Blue 661, 630, 596 
6hrs Brown + Pink + Green + Blue 660, 630, 596 
24hrs Brown + Green + Yellow 660, 629, 596 
 
Table 4. Time study of the formation of the porphyrazine, where the various colours 
represent the numerous phthalocyanine and porphyrazine fractions and intermediates 
that formed. 
 
From the table above it can be seen that though the colour change was instantaneous after 
the addition of lithium, the macrocyclic dyes are present but in low concentration.  
A UV-Vis assay was performed where a sample from the reaction mixture taken at the 
appropriate time point was added to a UV-vis cuvette (containing a fixed volume of THF) 
until an absorption of approximately 4 units was reached (figure 32). Based on this study 
it would appear that after four hours the concentration of the phthalocyanine product 
increased relative to the sample taken after 1, 2 and 3 hours. Further reaction aliquots 
were taken at 5, 6 and 24 hours, however there was no evident change in concentration of 
product (ie. The same volume of reaction mixture is required at each time point to bring 
about an absorption of 4 units), indicating that the reaction is complete after four hours.   
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Figure 32. UV-Vis spectra of porphyrazine Pc formation over time, illustrating that the 
reaction is complete after three hours of reaction. 
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2.3 Conclusion 
Two new 5-FU derivatives, 5 and 6, were prepared. Initial biological screening on these 
samples show a lower activity than the allyl derivative 4, indicating that the double bond 
is essential for the observed high biological activity of 4. 
Attempts were made to prepare a series of imidazole porphyrazines, however the self-
condensation of 1-phenyl-4,5-dicyanoimidazole could not be achieved due to the 
presence of the acidic proton of the imidazole. 1-Butyl-4,5-dicyanoimidazole was 
prepared and cross condensed with phthalonitrile. It was found that the target 
porphyrazine could be separated as the zinc derivative; the metal-free could not be 
separated from the unsubstituted phthalocyanine byproduct. Characterisation for 
porphyrazine 8 is based on UV-Visible anlaysis using SAPT theory.  
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2.4 Experimental 
 1,3-Nitrobenzyloxycarbonyloxymethyl-5-flourouracil, 1, and 1-
Nitrobenzyloxycarbonyloxymethyl-5-flourouracil, 2. 
5-FU (0.9 g, 7mmol) and formalin (1.16 ml, 15.4 mmol) were stirred at approximately 
60C for 45 mins.  The oily product was dried under vacuum and was then dissolved in 
dry acetonitrile (21 ml) followed by the addition of triethylamine (1.32 ml 9.45 mmol).  
The solution was then agitated under nitrogen at room temperature, followed by the slow 
addition of 4-nitrobenzyl chloroformate (1.87 g, 8.68mmol).  After stirring at room 
temperature for 3 hours the mixture was filtered and acetonitrile removed under reduced 
pressure.  The crude product was then dissolved in dichloromethane (21 ml) and washed 
three times with HCl (1 N), saturated NaHCO3 aq (21 ml x 2) and water (21 ml x 2).  The 
organic layer was dried over magnesium sulfate overnight, suction filtered and 
concentrated under vacuum.  The product was further purified using silica gel 
chromatography (5:2 chloroform : ethyl acetate) to yield 15% of compound 1 and 37% of 
compound 2. 
 
Characterization of product 1,3-Nitrobenzyloxycarbonyloxymethyl-5-flourouracil 2: 
1
HNMR 1H (400 MHz, DMSO – d6 )  (ppm) 5.347 (s, 2H, O-CH2-Ph), 5.719 (s, 2H, -
1
N-CH2-O), 5.878 (s, 2H, 
3
N-CH2-O), 7.564 – 7.690 (m, 8H, aromatic), 8.30 (d, 1H , CH-
CF). 
13
CNMR 13C (100 MHz, DMSO – d6 )  (ppm) 68.376 (s, 1C, O-CH2-Ph), 74.374 (s, 
1C, N-CH2-O), 123.894 (s, 4C, aromatic), 129.062 (s, 2C, aromatic), 129.124 (s, 2C, 
aromatic), 129.878, 130.223 (d, 1C, JF = 129.7 Hz, N-C=C-F), 137.893, 140.174 (d, 1C, 
JF = 867.656 Hz, C-F), 142.968 (s, 1C, N-CO-N), 147.646 (s, 1C, aromatic), 151.140 (s, 
1C, aromatic), 153.150 (s, 1C, O-CO-O), 156.32, 156.61 (d, 1C, JF =109.04 Hz, N-CO-
CF). 
19
FNMR 19F (DMSO – d6) –167.4 (d, 1F).  
ESI m/z: 571.2 (M+ Na
+
). 
MP: 88 – 91°C 
Elemental analysis: C22H17FN4O12; Calculated: %C = 48.18; %H = 3.12; %N = 10.22 
Found: %C = 49.75; %H = 3.62; %N = 9.67 
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Characterisation of 1-Nitrobenzyloxycarbonyloxymethyl-5-flourouracil 1: 
1
HNMR 1H (400 MHz, DMSO – d6 )  (ppm) 5.343 (s, 2H, CH2-Ph), 5.642 (s, 2H, N-
CH2-O), 7.686 (d, 2H, J= 2.8 Hz, aromatic), 8.160 (d, 1H, CH=CF), 8.272 (d, 2H, J= 2.2 
Hz, aromatic), 12.040 (bs, 1H, C-NH-C). 
13
CNMR 13C (100MHz, DMSO – d6 )  (ppm) 38.427 (s, 1C, O-CH2-Ph), 73.914 (s, 1C, 
O-CH2-N), 123.894 (s, 2C, aromatic), 129.167 (s, 2C, aromatic), 129.555 (d, 1C, JF = 
129.898 Hz, N-C=CF), 140.988 (d, 1C, JF = 862.92 Hz, C-F), 143.066 (s, 1C, N-CO-N), 
147.658 (s, 1C, aromatic), 149.608 (s, 1C, aromatic), 153.667 (1C, O-CO-O), 157.667 (d, 
1C, JF = 97.76 Hz, N-CO-CF). ). 
19
FNMR 19F (DMSO – d6) –168.605 (s, 1F).  
ESI m/z: 362.0 (M + Na
+
). 
MP: 158 - 162°C 
Elemental analysis: C13H10FN3O7; Calculated: %C = 46.03; %H = 2.97; %N = 12.39 
Found: %C = 46.97; %H = 3.36; %N = 11.44 
 
 
 
Preparation of a) 1-propyloxycarbonyloxymethyl-5-flourouracil, 5 and b) 1-
butyloxycarbonyloxymethyl-5-flourouracil, 6. 
5-FU (1.3 g, 10 mmol) and 37 w% formaldehyde in aqueous solution (1.9 mls, 25 mmol) 
were added to water.  The reaction was heated to 60C under agitation for 30 minutes. 
The resultant solution was concentrated and dried in a vacuum oven at 60C for 48 hours.  
The oily product was then dissolved in dry acetonitrile (30 ml) preceded by the addition 
of triethylamine (1.89 mls 13.5 mmol).  The solution was then agitated under nitrogen at 
room temperature, followed by the dropwise addition of (reaction a) propyl 
chloroformate (1.42 mls, 12.4 mmol.) and (reaction b) butyl chloroformate (1.61 mls, 
12.4 mmol).  After stirring at room temperature for 3 hours the mixture was filtered and 
acetonitrile removed under reduced pressure.  The crude product was then dissolved in 
dichloromethane (30 ml) and washed three times with HCl (1N), saturated NaHCO3 aq 
(30 ml x 2) and water (30 ml x 2).  The organic layer was dried over sodium sulfate 
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overnight, suction filtered and concentrated by rotary evaporation.  The product was 
isolated using silica gel chromatography (methanol-dichloromethane, 1:30, v/v) to yield 
37% of compound 5 and 40% of compound 6. 
 
Characterization of product 1-propyloxycarbonyloxymethyl-5-flourouracil 5.  
1
HNMR 1H (400 MHz, DMSO – d6 )  (ppm) 0.963 (t, 3H, J = 7.2 Hz, CH2-CH3),  
1.684 (h, 2H, J = 6.8 Hz, CH2-CH2-CH3), 4.137 (t, 2H, J = 6.4 Hz, O-CH2-CH2), 5.721 (s, 
1H, N-CH2-O), 8.210 (d, 1H, Ch-CF), 12.095 (bs, 1H, NH). 
13
CNMR 13C (100MHz, DMSO – d6 )  (ppm) 10.359 (s, 1C, CH3), 21.745 (s, 1c, CH2-
CH3), 69.984 (s, 1C, O-CH2-O), 73.535 (s, 1C, N-CH2-O), 129.912 (d, 1C, JF = 128.592 
Hz, C-CF), 140.964 (d, 1C, JF = 862.544 Hz, CF), 149.603 (s, 1C, N-CO-N), 153.972 (s, 
1C, O-CO-O), 157.653 (d, 1C, JF = 97.384  Hz, CO-CF). 
10
FNMR 19F  (DMSO – d6) –169.046 (d, 1F, Hz).  
ESI m/z: 269.1 (M + Na
+
). 
MP: 68 - 71°C 
Elemental analysis: C9H11FN2O5 Calculated: %C = 43.91; %H = 4.50; %N = 11.38 
Found: %C = 43.92; %H = 4.51; %N = 11.08 
Characterisation of 1-butyloxycarbonyloxymethyl-5-flourouracil 6. 
1
HNMR 1H (400 MHz, DMSO – d6 )  (ppm) 0.899 (t, 3H, J = 7.2 Hz, CH2-CH3), 1.343 
(h, 2H,  J = 7.6 Hz, CH2-CH2-CH3), 1.583 (p, 2H, J = 6.4 Hz, CH2-CH2-CH2), 4.122 (t, 
2H, J = 6.4 Hz, O-CH2-CH2), 5.586 (s, 2H, N-CH2-O), 8.155 (d, 1H, CH-CF), 12.055 (bs, 
1H, NH). 
13
CNMR 13C (100 MHz, DMSO – d6 )  (ppm) 13.982 (s, 1C, CH3), 18.717 (s, 1C, 
CH2-CH3), 30.330 (s, 1C, CH2-CH2-CH3), 38.253 (s, 1C, O-CH2), 73.534 (s, 1C, N-CH2-
O), 129.583 (d, 1C, JF = 128.592 Hz, CF-C-N), 140.957 (d, 1C, JF = 862.544 Hz, CF), 
149.603 (s, 1C, N-CO-N), 153.960 (s, 1C, O-CO-O), 157.655 (d, 1C, JF = 98.136 Hz, N-
CO-CF). 
19
FNMR 19F  (DMSO – d6) –169.062 (d, 1F, ). 
ESI m/z: 283.1 (M + Na
+
). 
MP: 46 - 48°C 
Preparation of 1-benzyl-28H,30H-tribenzo[b,g,l]imidazolo[4,5-q]porphyrazine 7. 
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1,2-Dicyanobenzene (86 mg, 0.43 mmol) and 1-benzyl-4,5-dicyanoimidazole (21 mg, 
0.06 mmol) were dissolved in pentanol (1 ml) and the solution was heated to reflux. 
Lithium was added and the resulting mixture was refluxed for 6 hrs. Upon cooling, acetic 
acid (2 ml.) was added and the mixture was stirred for 30 min. The solvent was 
evaporated off and the residue was taken up in methanol. The mixture was filtered. The 
product was separated by column chromatography (silica gel, and eluted with chloroform 
to clean the first fraction and then the eluent was changed to tetrahydrofuran to clean the 
second fraction). The two fractions were then fully separated by size exclusion 
chromatography on a bio-bead (SX-3) column using tetrahydrofuran as eluent. 
Characterisation of product: 
UV-Vis: (Chloroform) 682nm and 643nm. 
 
Synthesis of 1-Butyl-4,5-dicyanoimidazole : 
Triethylamine (1.38 ml, 0.01 mol), tetrabutylamonium iodide (5 mg) and 4,5-
dicyanoimidazole (1.25 g, 0.011 mol) were added to a solution of butanone (6.25mls) and 
stirred for 1hr at rt. Butyl bromide (1.2 ml, 0.01 mol) was added drop wise. The solution 
was refluxed for 2 days. The resulting solution was dissolved in Dichloromethane, 
washed with dilute ammonium solution followed by water, then dried over MgSO4 [
56
]. 
The solvent was evaporated to yield 69.54% brown oil crude product.  This was purified 
by silica get chromatography, eluent: Ethyl Acetate. Yielding 46.55% oil product. This 
was characterised by TLC, 
1
HNMR and 
13
CNMR.  
Characterisation of product: 
1
HNMR 1H (400 MHz, DMSO – d6 )  (ppm) 0.563 (t, 3H, J = 14.8 Hz, CH3-CH2), 
0.939 (m, 2H, J = 30 Hz, CH2-CH2-CH3), 1.446 (m, 2H, J = 29.6 Hz, CH2-CH2-CH2), 
3.724 (t, 2H, J = 14.8 Hz, CH2-CH2), 6.838 (s, H, N=CH-N). 
13
CNMR 13C (100 MHz, DMSO – d6 )  (ppm) 13.707 (s, 1C, CH3), 19.044 (s,1C, CH2-
CH3), 23.752 (s, 1C, CH2-CH2), 48.321 (s, 1C, N-CH2), 108.297 (s, 1C, N-C-CN), 
111.980 (s, 1C, N-C-CN), 123.402 (s, 1C, N-C-N), 141.404 (s, 2C, CN). 
ESI m/z: 197.1 (M + Na
+
). 
Elemental Analysis: C9H10N4 Calculated: %C = 62.05; %H = 5.79; %N = 32.16 Found: 
%C = 61.52; %H = 5.72; %N = 31.70 
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Synthesis of the 1-butyl-28H,30H-tribenzo[b,g,l]imidazolo[4,5-q]-zinc-porphyrazine 
8. 
1,2-Dicyanobenzene (178.84 mg, 1.40 mmol) and 1-benzyl-4,5-dicyanoimidazole (26.81 
mg, 0.15 mmol) were dissolved in pentanol (1.5 ml), the solution was heated to reflux 
(~150 °C). Lithium (20 mg) was added and the resulting mixture was refluxed for 6 hrs. 
Upon cooling, acetic acid (2 ml.) was added and the mixture was stirred for 30 min. The 
product was extracted from the solvent by a water/chloroform extraction and the 
chloroform was then evaporated off. The product was separated by column 
chromatography (silica gel, chloroform followed by tetrahydrofuran to pre-clean for the 
bio-bead column). The product was then further separated by size exclusion 
chromatography on a bio-bead (SX-3) column using tetrahydrofuran as eluent. This had 
to be repeated to achieve sufficient separation of the product mixture.  Next the purified 
porphyrazine was metallated. To do this pentan-1-ol (1 ml) and lithium were heated to 
50°C for 1hr, the Pc was added and after 20 min Zinc Acetate was added. The solution 
stirred at temperature over night. It was extracted using H2O/CHCl3, cleaned on a silica 
gel column, eluent THF, and purified on an SX-3 bio-bead column, eluent THF. The 
product was analysed by UV-Vis spectroscopy. 
Characterisation of product: 
UV-Vis: (Chloroform) 670 nm and 649 nm. 
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Chapter 3   Synthesis and Characterisation of a Calix[4]arene Porphyrin  
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3.1 Introduction 
The aim of this work was to prepare the starting material necessary for the preparation of 
a self-filled partial cone porphyrin derivative outlined in scheme 25 which involved four 
steps: 1) the methylation of the calixarene , 2) SnAryl reaction of di-methoxy 
calix[4]arene and 6-chloro-2-nitrobenzonitrile, 3) protection of the remaining hydroxyl 
group,  4) reduction of the nitrile group to an aldehyde. The last step involves the cross 
condensation of the partialcone calix[4]arene benzaldehyde with pyrrole and 
formaldehyde to yield the desired novel partial-cone calixarene porphyrin (scheme 25). 
 
Scheme 25.  The synthesis of self filled partial cone 5,11,17,23-tetra-t-butyl-27-hydroxy-
26,28-dimethoxy-25-(3-[2-chloro-benzaldehyde])calix[4]arene . 
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3.2 Synthesis of Self Filled Partial Cone Calix[4]arene 
 
OOH OHO
Me Me
OHOH OHOH
K2CO3/MeI
9  
 
Scheme 26. Preparation of 5,11,17,23-tetra-tert-butyl-25,27-dihydroxy-26,28-dimethoxy  
calix[4]arene. 
 
The preparation of the self filled partial cone was achieved as previously described, in 
four stages. In the first step tetra-tert-butyl-calix[4]arene was partially etherified using 
potassium carbonate and methyl iodide  which were dissolved in DMF and refluxed for 
one hour to produce a mixture of di- and tri-methoxy calix[4]arene (scheme 26). 
Purification was carried out by flash chromatography on a silica gel column using 9:1 
hexane : ethyl acetate as mobile phase to give the distal-1,3-dimethoxy-calix[4]arene in a 
30% yield.  
Only partial etherification is observed in this reaction since a weak base, K2CO3, was 
employed, thereby avoiding substitution at all four hydroxy positions. The mechanistic 
reason that only distal-1,3-di-mehoxycalix[4]arene is obtained is because the two 
remaining OH groups are stabilised by H-bonding making them less acidic. To fully 
substitute the calix[4]arene a strong base such as NaH in an aprotic solvent would be 
required.
57
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Scheme 27. Preparation of 5,11,17,23-tetra-tert-butyl-25-hydroxy-27-(-2-chloro-
benzonitrile)-26,28-dimethoxy calix[4]arene(10) . 
 
In the second step, the dimethoxy calix[4]arene , 6-chloro-2-nitrobenzonitrile and 
potassium carbonate were dissolved in DMF and stirred at room temperature for twenty 
four hours under vacuum (scheme 27). This brought about an SnAryl displacement of the 
nitro group of 6-chloro-2-nitrobenzonitrile by the 1,3-dimethoxycalixarene. The product 
was purified by silica gel chromatography using hexane : ethyl acetate 10:1 as the eluent 
to give 5,11,17,23-tetra-tert-butyl-25-hydroxy-27-(-2-chloro-benzonitrile)-26,28-
dimethoxycalix[4]arene (10) in the partial cone conformation in 24% yield. It should be 
noted that double substitution of the 1,3-dimethoxycalixarene is not observed, only single 
substitution occurs. 
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Figure 33. 
1
HNMR of Self Filled Partial Cone 5,11,17,23-tetra-t-butyl-27-hydroxy-
26,28-dimethoxy-25-(3-[2-chloro-benzonitrile])calix[4]arene 10. 
 
Outlined in figure 33 is the 
1
H NMR of compound 10. The tert-butyl peaks are found at 
0.8 ppm, 1.3 ppm and 1.45 ppm. The singlet at 3.65 ppm represents the two methoxy 
groups while the doublets at 3.2 ppm, 4.05 ppm and the overlapping AB pattern doublets 
at 3.8 ppm can be assigned to the protons of the calixarene bridging methylene groups. 
The triplet at 3.1 ppm and the doublets at 3.95 ppm and 5.68 ppm represent the protons of 
the chlorobenzonitrile substituent. It is important to note the position of these three 
protons, as they are much further up field than one would normally expect to find 
aromatic protons. This information confirms that the product is indeed in the partial cone 
conformation, as part of the benzonitrile substituent lies within the aromatic annulus of 
the calixarene resulting in the aniosotropic shielding of two of the benzonitrile protons 
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(3.95 ppm and 3.95 ppm). The shielding provided by the calixarene is greatest for the 
proton para to the cyano group since it points directly into ring C of the calixarene and 
appears at 3.1 ppm. The proton para to the chloro group is embedded a little less deep in 
the annulus and is therefore shifted further down field to 3.95 ppm. The third aromatic 
proton, para to the ether linkage on the benzonitrile substituent, sits at the rim of the 
calixarene and is therefore influenced only slightly by the shielding effect, thus it is found 
at 5.58 ppm. The remaining signals from 6.35 ppm to 7.5 ppm can be assigned to the 
calixarene aromatic protons. 
The reaction of di-methoxycalix[4]arene with 6-chloro-2-nitrobenzonitrile to produce 10 
was repeated at higher temperature, 60°C, to determine if higher yields could be procured 
and if higher reaction temperature would affect the conformation of the product. 
However, the temperature increase had no effect on either yield or reaction time (ie. the 
same reaction time was required at 60
o
C) and the product was made solely in the partial 
cone conformation as determined by 
1
H NMR. 
The application of microwave assisted synthesis for the preparation of 10 was also 
explored. The advantages of microwave assisted synthesis include, 1) speed with which 
the reaction can be completed, 2) this procedure requires a minimal quantity of solvent. 
The initial method emloyed involved using a dry mix of the reagents in a 700W 
microwave oven at atmospheric pressure, however no reaction took place. It was decided 
to mix the reagents with DMF to form a paste, under these conditions the reaction went to 
completion in two minutes giving 10 in a 15% yield after chromatography. The resulting 
product was also found to be solely in the partial cone conformation by 
1
H NMR. Since 
the yield of 10 was lower than the conventional room temperature method, microwave 
assisted synthesis was not further developed for the preparation of 10. 
At this point a control experiment was carried out where phenol, in place of 1,3-
dimethoxycalixarene, was treated with 6-chloro-2-nitrobenzonitrile under the same 
conditions used to prepare 10. No product was produced under these conditions. From 
this result it would appear that for nucleophilic displacement to take place with 2-chloro-
6-nitrobenzonitrile the presence of the calixarene is required, or in other words there is a 
‘calixarene effect’ which plays a vital role in the substitution process. It first should be 
noted that nucleophilic substitution cannot occur on the lower rim of the dimethoxy 
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calixarene using 2-chloro-6-nitrobenzonitrile as substrate. Based on molecular models the 
methyl group substituents on the lower rim sterically interact with the ortho substituent to 
the nitro leaving group of 2-chloro-6-benzonitrile preventing displacement onto the lower 
rim from occurring. Consequently, the only possible site of reaction is on the upper rim, 
and this is achieved by the rotation of the phenoxide intermediate through the annulus of 
the calixarene (scheme 28).  When the phenoxide is present within the annulus of the 
calixarene it becomes more reactive since solvation is absent within the calixarene 
annulus (a hydrophobic environment). Furthermore, it is possible for 6-chloro-2-
nitrobenzonitrile to perch into the upper rim of the calixarene, where it is perfectly 
oriented for displacement by the calixarene phenoxide. It is for these reasons that a 
reaction is observed in the case of 1,3-dimethoxycalixarene and not for phenol. 
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Scheme 28. Mechanistic representation of partial cone formation. 
58
 
 
To determine the stability of the partial cone conformation of 10 a sample was analysed 
by 
1
H NMR at temperatures ranging from room temperature to 100°C. The results, figure 
33, agreed with those previously found for a similar calix[4]arene prepared using 3-
nitrophthalonitrile (as outlined in the literature review, section 1.22). 
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Figure 33. 
1
H NMR temperature study of the self filled partial cone 5,11,17,23-tetra-tert-
butyl-27-hydroxy-26,28-dimethoxy-25-(3-[2-chloro-benzonitrile])calix[4]arene 10. 
 
As with the phthalonitrile calix[4]arene discussed in the literature review, in this 
temperature study the triplet representing the aromatic benzonitrile H5 proton at 3.4ppm 
(at 21°C) gets shifted slightly downfield with an increase in temperature. This is thought 
to be due to a slight tilt of the calixarene phenyl ring (C ring). 
The third step in this synthesis was the conversion of 10 to the trimethoxy calixarene 11 
which was carried to prevent the phenoxy group from interfering with the reduction of 
the nitrile in the next stage of the synthesis. This methylation reaction required dissolving 
10 and sodium hydride in a 50:50 DMF:THF solution and heating to 60°C (scheme 29). 
Methyl iodide was then added dropwise and the reaction was stirred for twenty four 
hours. The product was purified by silica gel chromatography, using a mobile phase of 
90:10 hexane : ethyl acetate, which yielded 89% of 11. It should be noted that 11 is 
prepared solely in the partial cone conformational, that is no conformational change is 
observed in this reaction.  
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Scheme 29.  Preparation of 11. 
 
3.3 Reduction of 5,11,17,23-tetra-t-butyl-27-hydroxy-26,28-dimethoxy-25-(3-[2-
chloro-benzonitrile])calix[4]arene 10 to 5,11,17,23-tetra-t-butyl-27-hydroxy-26,28-
dimethoxy-25-(3-[2-chloro-benzaldehyde])calix[4]arene 11. 
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Scheme 30. Reduction of 11  to benzaldehyde 12. 
 
This is the fourth and final step in the preparation of 12. The aim is to reduce the nitrile 
group of the benzonitrile substituent to an aldehyde, which is required for porphyrin 
synthesis (scheme 30). 
 
   72 
Me
Cl
Me
N
O O
O
O
Me
Cl
Me
O O
O
O
O
H
1) DIBAL-H/THF
2) HCl
X
Me
Me
1211  
Scheme 31. Failure of DIBAl-H to reduce benzonitrile to benzaldehyde, method 1. 
 
The first method of reducing the nitrile to an aldehyde involved dissolving 11 in 
anhydrous THF, cooling the reaction mixture to 0°C and slowly adding the reducing 
agent DIBAl-H, then allowing the reaction to proceed over three hours at room 
temperature (scheme 31). The reaction was quenched with methanol and aqueous HCl.
59
 
However, the 
1
H NMR of the crude product showed that only starting material was 
recovered, that is no reduction took place via this method which was consistent with TLC 
analysis.  
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Scheme 32. Attempt using  DIBAl-H to reduce benzonitrile to benzaldehyde, method 2. 
 
In the second DIBAl-H method, the calixarene benzonitrile was dissolved in anhydrous 
DCM. DIBAl-H was added slowly under N2 and the solution was heated to reflux and 
stirred overnight (scheme 32). The reaction solution was added to a mixture of 10% 
H2SO4 and ice and finally extracted with DCM.
60
 The resulting crude product was 
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analysed by 
1
H NMR; however once again the spectrum revealed that no reduction took 
place. 
It was concluded that DIBAl-H is physically too large to react with the nitrile within the 
cavity of the calixarene thus preventing the formation of the aldehyde. 
 
Figure 34.  Hyperchem software version 7.51 illustrations of 5,11,17,23-tetra-tert-butyl-
27-(-6-chloro-benzonitrile)-25,26,28-trimethoxy calix[4]arene 11, viewing the calixarene 
basked from the side  and from above respectively. The yellow feature represents the 
nitrile unit. 
 
To illustrate this point the 3-D illustrations (Hyperchem software version 7.51 ) for 11 are 
shown in figure 34. It is evident that there is a high degree of congestion around the 
nitrile group making it difficult for the DIBAl-H to attack, and it is for this reason that the 
reaction fails. 
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Scheme 33. Lithium aluminium hydride reduction of calixarene benzonitrile to 
calixarene benzaldehyde, method 3. 
 
A third attempted procedure for the conversion of 11 to 12 was employed using lithium 
aluminium hydride as the reducing agent (scheme 33). This agent is much smaller than 
DIBAl-H yet is documented in the literature as being sufficiently strong to reduce a 
nitrile group to an aldehyde, and has been exploited to this end in many papers. It is 
worth noting that these reactions were carried out on a small scale, usually <100 mg. The 
preparation involved dissolving 11 in diethyl ether and reducing the temperature to -8°C. 
LiAlH4 was added slowly and the solution temperature was raised to +3°C, at which it 
was maintained for 1hr with stirring. The reaction solution was then quenched with 5N 
sulphuric acid, extracted into diethyl ether, washed with water and dried over magnesium 
sulphate.
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 The crude product was analysed by 
1
H NMR and displayed a proton signal in 
the aldehyde region at 9.71 ppm, indicating that partial reduction had taken place, 
however starting material was still present. Since both 11 and 12 have the same rf value 
by TLC, making separation impossible by chromatography, it was decided to repeat the 
reduction on the isolated crude product it was found after the second conversion the 
aldehyde signal was still present, however starting material was also present. A third 
attempt, using the crude product from the second attempt, failed to give any reduction, 
and the originally reduced aldehyde disappeared, thus a clean, isolated sample for 
analysis was not obtained. One possible cause for the failed reaction attempts may have 
been due to too much moisture in the system, which would have quenched the LiAlH4 
before it could reduce the nitrile. This effect would have been compounded due to the 
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small scale of the reactions (100mg). However, eliminating this issue by using new dry 
solvents, glassware that was oven dried and purging all glassware with N2 prior to use did 
not solve the problem and after numerous attempts this preparation could not be repeated.  
 
Figure 35. 
1
H NMR of 5,11,17,23-tetra-tert-butyl-27-(-6-chloro-benzaldehyde)-25,26,28-
trimethoxy calix[4]arene 12 resulting from LiAlH4 reduction of 11. 
 
While the 
1
HNMR shown in figure 35 is not as clean as would be ideal, the protons from 
both the calixarene and the benzaldehyde substituent can be seen. The tert-butyl groups 
are present from 0.5ppm – 1.5 ppm, the three methoxy units appear at 3.65 ppm, the 
bridging methylene protons signals appear as doublets at 3.2 ppm and 4.1 ppm and the 
overlapping pair of doublets appear as expected at 3.8 ppm. The benzaldehyde signals are 
displayed as a triplet at 3.1 ppm and doublet at 4.2 ppm. The third benzaldehyde doublet 
signal occurs at 5.7 ppm. The aromatic calixarene protons are present between 6.8 ppm 
and 7.6 ppm and the aldehyde signal is present at 10.25 ppm. 
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Scheme 34. Attempt using PtO2 to reduce benzonitrile to benzaldehyde, method 4. 
 
The fourth method explored to prepare 12 involved using platinum oxide dissolved in 
80% aqueous formic acid. This method was chosen because unlike the DIBAl-H method 
or the LiAlH4 method, this preparation was not sensitive to water or moisture. In this 
method, 11 and platinum oxide are dissolved in 80% formic acid and stirred at 60°C 
overnight (scheme 34). A water-diethyl ether extraction was carried out and the resulting 
solution was dried over magnesium sulphate.
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 The 
1
H NMR of the crude product 
initially looked promising, showing a new peak at 8.6 ppm, however the addition of D2O 
to the sample followed by a second 
1
H NMR analysis revealed that the peak at 8.6 ppm 
disappeared, confirming that the nitrile had been converted to the acid under these 
conditions.  
 
An alternative synthetic approach to preparing the target partial cone aldehyde is to treat 
1,3-dimethoxycalixarene with a series of appropriate aryl aldehydes via an SNaryl 
reaction. Attempts had been made previously in the Nolan group to prepare partial cone 
aldehydes under these conditions however. These attempts failed, however, all previous 
attempts carried out were at room temperature, it may be possible that this synthetic 
approach may work however higher temperatures may need to be employed.  
The first reaction carried out was the treatment of distal-1,3-dimethoxy calixarene with 6-
chloro-2-fluorobenzaldehyde (scheme 36). Reactions were set-up at three different 
temperature, 60
o
C, 80
o
C and 100
o
C in DMF. No products were observed at either 60
o
C or 
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80
o
C after four days of reaction. However, at 100
o
C a new spot, albeit faint, was observed 
by TLC after four days. The product was isolated by silica gel chromatography using 
10% ethyl acetate/hexane as eluent. The 
1
H NMR of the isolated product showed the 
presence of three aldehyde peaks, with one of the observed peaks corresponding to the 
aldehyde proton of 6-chloro-2-fluorobenzonitrile (contaminent). Peaks were also 
observed between 3-6 ppm which are typical for calixarene, however the spectrum was 
rather complicated indicating the presence of more than one calixarene product.  
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Scheme 35. High temperature SNAryl reaction to prepare aldehyde. 
 
It is possible that this mixture consists of starting material and two calixarene aldehyde 
products as shown in scheme 35. It should be noted that both fluorine and chlorine are 
potentially good leaving groups for SNAryl reactions, it is then possible at high 
temperature that substitution is occurring at both the 2 and 6 sites of 6-chloro-2-
fluorobenzonitrile thereby giving a mixture of products 12 and 13. Attempts to further 
separate this mixture were unsuccessful and considering that only 10 mg of this mixture 
was isolated from a 100 mg scale reaction it was decided not to pursue this approach any 
further. 
A second attempt to prepare a partial cone aldehyde was carried out using 6-chloro-2-
nitrobenzaldehyde (scheme 36) at high temperature. However no observable product was 
found after 48 hours by TLC, this approach was not further pursued.  
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Scheme 36. High temperature SNAryl reaction to preparethe aryl  aldehyde. 
 
3.4 Microwave assisted synthesis of aldehyde 
 
Finally the possibility of introducing a benzaldehyde into the calixarene by an SNAryl 
reaction was explored. An SNAryl substitution was attempted between distal-1,3-
dimethoxy calixarene and a series of aryl substrates listed in table 5. It was hoped that the 
variation in the heat profile generated by the microwave assisted technique would 
promote the reaction to proceed where the thermal methodology had failed.
63
 However 
the reactions attempted using the benzaldehyde substrates did not give any substituted 
calixarene products, only the reaction with 6-chloro-2-nitrobenzonitrile gave product.  
 
 
 
 
 
 
 
 
   79 
MeMe
OH O
O
O
OOH OHO
Me Me
DMF
K2CO3
Aryl substrate
Microwave
R
 
 
Aryl Substrate Observation 
CN
Cl
NO2  
Reaction observed – compound 10 
isolated 
Cl
NO2
O
H
 
No Reaction 
Cl
F
O
H
 
No Reaction 
NO2
O
H
Cl
 
No Reaction 
F
O
H
 
No Reaction 
O
H
F
 
No Reaction 
 
Table 5. Attempted open atmosphere microwave assisted synthesis of calixarene 
aldehydes. 
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3.5 Conclusion 
 
The target of this work was to prepare calixarene 12. Attempts at converting the nitrile 
derivative 11 to 12 using various reduction methodologies failed, only one method using 
LiAlH4/H2SO4 yielded an aldehyde product as identified by 
1
H NMR. However, this 
method was not reproducible. A high temperature thermal SNAryl reaction was attempted 
to prepare the aldehyde directly from distal-1,3-dimethoxycalixarene, only trace amounts 
of an inseparable mixture of calixarene products could be isolated. 
Microwave assisted SNAryl displacements were attempted using various aryl aldehyde 
substrates and distal-1,3-dimethoxycalixarene, unfortunately, none of these reactions 
yielded any substituted calixarene product. Work on this project was discontinued due to 
time restrictions. 
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3.6 Experimental 
5,11,17,23-tetra-tert-butyl-25,27-dihydroxy-26,28-dimethoxy  calix[4]arene . 
Tetra-tert-butyl-calix[4]arene (2g 3.09mmol), methyl iodide (0.75ml, 12.35mmol) and 
potassium carbonate (4.25g, 30mmol) were dissolved in DMF (25ml) and refluxed at 70
o
 
for 1 hr. The reaction mixture was then poured onto iced water (100ml), causing the 
product to crash out. The crude product was extracted with ethyl acetate (3 x 30ml). The 
organic layer was washed with water (30ml) then brine (30ml), dried using magnesium 
sulphate and rotary evaporated, This was followed by recrystalisation from ethanol. The 
product was adsorbed onto silica and purified by column chromatography, stationary 
phase silica, mobile phase Hexane: ethyl acetate 90:10, 67% yield (1.405g). The product 
was analysed by TLC and 
1
H NMR. 
Characterisation of product: 
 
1
HNMR 1H (400MHz, CDCl3 – d6 )  (ppm) 0.800 (s, 18H, 2 x t-bu), 1.248 (s, 9H, t-
bu), 1.442 (s. 9H, t-bu), 3.223 (d, 2H, J=12.8 Hz, Ph-CH2-Ph), 3.629 (s, 6H, 2 x OMe), 
3.828 (q, 4H, J=15.2 Hz, 2 x Ph-CH2-Ph), 4.011 (d, 2H, J=9.6 Hz, Ph-Ch2-Ph), 6.266 (s, 
H, Ar-H), 6.734 (s, H, Ar-H), 7.056 (s, H, Ar-H), 7.508 (s, H, Ar-H). 
ESI m/z: 699 (M + Na
+
) 
MP: 254 - 256°C 
IR: (KBr [cm
-1
]): 3440cm
-1
 υ(O-H); 2921cm-1 υ(But) 
 
5,11,17,23-tetra-tert-butyl-25-hydroxy-27-(-2-chloro-benzonitrile)-26,28-dimethoxy 
calix[4]arene, 9: 
5,11,17,23-tetra-tert-butyl-25,27-dihydroxy-26,28-dimethoxy calix[4]arene (0.1g, 
0.14mmol), 6-chloro-2-nitrobenzonitrile (0.1g, 0.57mmol) and potassium carbonate 
(0.08g, 0.57mmol) were dissolved in DMF (7mls) and stirred at room temperature over 
one day under vacuum. The resulting solution was poured onto ice-water, and purified by 
silica gel chromatography from hexane : ethyl acetate 10:1, yielding a white solid, 24% 
yield (0.043g). 
Characterisation of product: 
1
HNMR 1H (400MHz, CDCl3 – d6 )  (ppm) 0.8004 (s, 18H, 2 x t-bu), 1.270 (s, 9H, t-
bu), 1.432 (s. 9H, t-bu), ), 3.116 (t, H, J=13.2 Hz, Ar-H-CN), 3.223 (d, 2H, J=13.2 Hz, 
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Ph-CH2-Ph), 3.647 (s, 6H, 2 x OMe), 3.827 (q, 4H, J=9.6 Hz, 2 x Ph-CH2-Ph), 3.966 (d, 
H, J=8.4 Hz, Ar-H-CN), 4.043 (d, 2H, J=12.8 Hz, Ph-CH2-Ph), 5.683(d, H, J=8.4 Hz, Ar-
H-CN), 6.267 (s, H, Ar-H), 6.734 (s, H, Ar-H), 7.056 (s, H, Ar-H), 7.508 (s, H, Ar-H). 
ESI m/z: 834 (M + Na
+
) 
IR: (KBr [cm
-1
]): 3330cm
-1
 υ(O-H); 2921cm-1 υ(But), 2218cm
-1
 υ(CN) 
MP: 249 - 251°C 
Elemental analysis: C53H62O4NCl; Calculated: %C = 78.35; %H = 7.69; %N = 1.72 
Found: %C = 78.39; %H = 7.84; %N = 1.63 
 
Microwave Synthesis - General Method: 
5,11,17,23-tetra-tert-butyl-25,27-dihydroxy-26,28-dimethoxy calix[4]arene (0.1g, 
0.14mmol), 6-chloro-2-nitrobenzonitrile (0.1g, 0.57mmol) and potassium carbonate 
(0.08g, 0.57mmol) were dissolved in 2 drops of DMF in an open glass vial and placed in 
a 700W domestic microwave oven on full power, at atmospheric pressure for 1min, 2min 
and 4min. The resulting paste was purified by silica gel chromatography from hexane : 
ethyl acetate 10:1, yielding a white solid (15% yield). The isolated product was 
characterised by 
1
H NMR, resulting in the same spectral data as that given above for the 
conventional thermal method of synthesis. 
The same stoichiometric ratios were used in all reactions 
 
5,11,17,23-tetra-tert-butyl-27-(-6-chloro-benzonitrile)-25,26,28-trimethoxy 
calix[4]arene 10: 
A mixture of 5,11,17,23-tetra-tert-butyl-25-hydroxy,27-(-6-chloro-benzonitrile)-26,28-
dimethoxy calix[4]arene (0.06g, 0.08mmol) and sodium hydride (0.005g, 0.250mmol) 
were dissolved in THF:DMF (50:50, 7mls) and heated to 60°C under N2. Methyl iodide 
(3.5mls, 6mmol) was added slowly and the reaction solution was stirred over one day. 
The resulting solution was poured in ice water, extracted with dichloromethane and dried 
over magnesium sulphate. The solvent was removed and the crude product was purified 
by silica gel chromatography. Mobile phase hexane : ethyl acetate 90:10, yielding a white 
solid in 89% yield, (0.049g). The product was analysed by TLC and 
1
H NMR. 
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Characterisation of product: 
1
HNMR 1H (400MHz, CDCl3 – d6 )  (ppm) 0.787 (s, 18H, 2 x t-bu), 1.292 (s, 9H, t-
bu), 1.442 (s. 9H, t-bu), ), 3.068 (t, H, J=13.2 Hz, Ar-H-CN), 3.284 (d, 2H, J=13.2 Hz, 
Ph-CH2-Ph), 3.497 (s, 3H, OMe), 3.582 (s, 6H, 2 x OMe), 3.729 (q, 4H, J=9.6 Hz, 2 x 
Ph-CH2-Ph), 4.022 (d, H, J=8.4 Hz, Ar-H-CN), 4.157 (d, 2H, J=12.8Hz, Ph-CH2-Ph), 
5.631 (d, H, J=8.4 Hz, Ar-H-CN), 6.163 (s, H, Ar-H), 6.598 (s, H, Ar-H), 7.112 (s, H, Ar-
H), 7.435 (s, H, Ar-H). 
ESI m/z: 843 (M + NH3), 848.8 (M + Na
+
) 
MP: 237 - 239°C 
 
 
5,11,17,23-tetra-tert-butyl-27-(-6-chloro-benzaldehyde)-25,26,28-trimethoxy 
calix[4]arene 11.
 
Attempted Method #1 
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5,11,17,23-tetra-tert-butyl-27-(-6-chloro-benzonitrile)-25,26,28-trimethoxy calix[4]arene  
(0.08g, 0.115mmol) was dissolved in anhydrous THF (5mls), cooled to 0°C and DIBAl-H 
(1.0 M solution in hexane, 0.02ml) was added dropwise with stirring. The solution was 
allowed to warm to room temperature and stirred for three hours. The solution was again 
cooled to 0°C and treated with MeOH (0.5mls) and stirred for five minutes. The reaction 
solution was next poured into 0.5N aqueous HCl (15mls) followed by extraction with 
ethyl acetate. The organic layer was washed with water and brine and dried over 
magnesium sulphate.  The resulting solution was analysed by TLC and 
1
HNMR. 
 
 
Attempted Method #2 
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5,11,17,23-tetra-tert-butyl-27-(-6-chloro-benzonitrile)-25,26,28-trimethoxy calix[4]arene  
(0.06g, 0.08mmol) was dissolved in anhydrous DCM, DIBAl-H (1.0M solution in 
hexane, 0.053mls) was added slowly under N2 and the solution  heated to reflux and 
stirred over night. The reaction solution was added to a mixture of 10% H2SO4 and ice 
and extraction was carried out with DCM. Magnesium sulphate was used as a drying 
   84 
agent and the remaining solvent was evaporated off. The resulting solution was analysed 
by TLC and 
1
HNMR 
 
Attempted Method #3 
66
 
5,11,17,23-tetra-tert-butyl-27-(-6-chloro-benzonitrile)-25,26,28-trimethoxy calix[4]arene 
(0.055g, 0.076mmol) and platinum oxide (0.0018g, 0.008mmol) were dissolved in 80% 
aqueous formic acid (3mls) and stirred at 60°C over night. A water - diethyl ether 
extraction was carried out and the resulting solution was dried over magnesium sulphate. 
The resulting crude product was analysed by TLC and 
1
HNMR. 
 
Characterisation of  crude product:  
1
HNMR 1H (400MHz, CDCl3 – d6 )  (ppm) 0.786 (s, 18H, 2 x t-bu), 1.290 (s, 9H, t-
bu), 1.440 (s. 9H, t-bu), 2.589 (t, H, J=13.2 Hz, Ar-H-CN), 3.099 (d, 2H, J=13.2 Hz, Ph-
CH2-Ph), 3.740 (s, 9H, 3 x OMe), 3.924 (q, 4H, J= 9.6 Hz, 2 x Ph-CH2-Ph), 4.054 (d, 2H, 
J=12.8 Hz, Ph-CH2-Ph), 4.184 (d, H, J=8.4 Hz, Ar-H-CN),  5.631 (d, H, J=8.4 Hz, Ar-H-
CN), 6.162 (s, H, Ar-H), 6.601 (s, H, Ar-H), 7.112 (s, H, Ar-H), 7.438 (s, H, Ar-H), 8.572 
(s, H, Ar-COOH). 
 
Attempted Method #4 
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5,11,17,23-Tetra-tert-butyl-27-(-6-chloro-benzonitrile)-25,26,28-trimethoxy calix[4]arene  
(0.077g, 0.107mmol) was dissolved in diethyl ether (2mls) and brought to -8°C. Lithium 
aluminium hydride (0.11mls, 0.107mmol) was added and the solution was brought to 
+12°C and then back down to +3°C, at which it was maintained for 1hr with stirring. The 
reaction solution was then quenched with 5N sulphuric acid, extracted and washed with 
diethyl ether and dried over magnesium sulphate. The product was analysed by TLC and 
1
H NMR. 
 
 
Characterisation of crude product:  
1
HNMR 1H (400MHz, CDCl3 – d6 )  (ppm) 0.787 (s, 18H, 2 x t-bu), 1.292 (s, 9H, t-
bu), 1.442 (s. 9H, t-bu), 3.068 (t, H, J=13.2 Hz, Ar-H-CN), 3.254 (d, 2H, J=13.2 Hz, Ph-
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CH2-Ph), 3.682 (s, 9H, 3 x OMe), 3.729 (q, 4H, J=9.6 Hz, 2 x Ph-CH2-Ph),4.157 (d, 2H, 
J=12.8 Hz, Ph-CH2-Ph), 4.222 (d, H, J=8.4 Hz, Ar-H-CN),  5.681 (d, H, J=8.4 Hz, Ar-H-
CN), 6.293 (s, H, Ar-H), 6.758 (s, H, Ar-H), 7.112 (s, H, Ar-H), 7.435 (s, H, Ar-H), 
10.310 (s, H, Ar-CHO). 
 
High temperature attempt to prepare 125,11,17,23-tetra-tert-butyl-25-hydroxy-27-(-
2-chloro-benzonitrile)-26,28-dimethoxy calix[4]arene, 9: 
5,11,17,23-tetra-tert-butyl-25,27-dihydroxy-26,28-dimethoxy calix[4]arene (0.1g, 
0.14mmol), 6-chloro-2-nitrobenzonitrile (0.1g, 0.57mmol) and potassium carbonate 
(0.08g, 0.57mmol) were dissolved in DMF (7mls) and stirred at 100
o
C over four days 
under vacuum. The resulting solution was poured onto ice-water, and purified by silica 
gel chromatography from hexane : ethyl acetate 10:1, yielding a trace of white solid, (5 
mg). 
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